Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.06 -2.07%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CrowdStrike shares jump on earnings beat, raised outlook
- Lantronix (LTRX) Reports In-Line Q4 EPS; Offers Guidance
- Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
